Arbutus Biopharma CEO tenders 24,655 shares at $5

The President and CEO held 47,682 shares directly after the issuer accepted the tendered shares for payment on October 1, 2026.

Rhea-AI Filing Summary

Arbutus Biopharma Corp's President and CEO, Lindsay Androski, returned 24,655 common shares to the issuer in its tender offer at $5.00 per share on October 1, 2026. The issuer took up and accepted the shares for payment that day. Androski held 47,682 common shares directly following the transaction. No Rule 10b5-1 plan is reported.

Insider Trade Summary

Disposition: 24,655 shares

Disposition 1 txn

Insider Androski Lindsay

Role President and CEO

Type	Security	Shares	Price	Value
Disposition	Common Shares F1	24,655	$5.00	$123K

Holdings After Transaction: Common Shares — 47,682 shares (Direct)

Footnotes (1)

1. F1. Represents common shares tendered to the Issuer pursuant to the Issuer's tender offer. The Issuer took up and accepted the common shares for payment on October 1, 2026.

Key Figures

Common shares tendered: 24,655 common shares Price per share: $5.00 per share Direct common shares following transaction: 47,682 common shares

3 metrics

Common shares tendered 24,655 common shares Tendered to the issuer on October 1, 2026

Price per share $5.00 per share Tender offer transaction on October 1, 2026

Direct common shares following transaction 47,682 common shares Held by Lindsay Androski following the transaction

Key Terms

tender offer, took up, accepted for payment

3 terms

tender offer financial

"pursuant to the Issuer's tender offer"

A tender offer is a proposal made by a person or company to buy shares from existing shareholders at a set price, usually higher than the current market value, within a specific time frame. It matters to investors because it can lead to a change in ownership or control of a company, and shareholders must decide whether to sell their shares at the offered price.

took up financial

"The Issuer took up and accepted"

accepted for payment financial

"accepted the common shares for payment"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ABUS shares did President and CEO Lindsay Androski tender, and at what price?

Lindsay Androski tendered 24,655 common shares at $5.00 per share on October 1, 2026. The issuer accepted the shares for payment that day, and no Rule 10b5-1 plan is reported.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/07/2026 - 04:09 PM Accepted by SEC EDGAR 10/07/2026 - 04:09 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Androski Lindsay

(Last) (First) (Middle)

C/O ARBUTUS BIOPHARMA CORPORATION

701 VETERANS CIRCLE

(Street)

WARMINSTER PENNSYLVANIA 18974

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Arbutus Biopharma Corp [ ABUS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	10/01/2026		D		24,655(1)	D	$5	47,682	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents common shares tendered to the Issuer pursuant to the Issuer's tender offer. The Issuer took up and accepted the common shares for payment on October 1, 2026.

Remarks:

	/s/ Tuan Nguyen as attorney-in-fact for Lindsay Androski	10/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)